In this episode, Mike Favet, the new CEO of NeuroPace, shares his personal story into Medtech and reveals his plans for one of Medtech’s pioneers, NeuroPace. What convinced him to become CEO? What changes will he make at NeuroPace?
Michael Favet has 20 years of senior management experience with medical technology companies. He has served on the NeuroPace Board of Directors since 2016 and served as the company’s Chief Commercial Officer prior to assuming the role of Chief Executive Officer in 2019.
Prior to joining NeuroPace, Mr. Favet held various executive-level positions for companies including Advanced Cardiac Therapeutics, Sonitus Medical, Ventus Medical, Boston Scientific and Guidant. Most recently, Mr. Favet was a managing director for KCK’s medtech group, part of a fund for medical technology investments.
Mr. Favet received a BS in Mechanical Engineering from the University of Illinois and an MBA from the University of Minnesota.
Meet Our Host
A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.